Literature DB >> 11195013

Effects of enzyme replacement therapy in thirteen Japanese paediatric patients with Gaucher disease.

H Ida1, O M Rennert, M Kobayashi, Y Eto.   

Abstract

UNLABELLED: To determine treatment effects in the unique and previously internationally unreported Japanese paediatric patient population with Gaucher disease (GD), we analysed six response parameters among 13 patients given enzyme replacement therapy (ERT). Also to obtain insights into optimising maintenance dosing, through subgroup analysis we retrospectively examined effects of three ERT dose reduction schedules from a starting regimen of 60 U/kg of body weight every 2 weeks. Our patients included 11 males and two females, 11 individuals with possible type 1 and two individuals with type 3b GD, six individuals with the L444P/F2131 genotype and five with the L444P/L444P genotype, and five who had been splenectomised. Despite different mutation prevalence, Japanese patients with GD, like their counterparts from other ethnic groups, generally benefitted from ERT. However, early and marked ERT dose reduction (from 60 U/kg to 30 or 15 U/ kg every 2 weeks within < or =6 months) was associated with insufficient improvement of mean haemoglobin level and relative height and with insufficient improvement or worsening of platelet count. Only the subgroup given 60 U/kg of ERT every 2 weeks for 36 months had significant improvement in mean haemoglobin, platelet count, angiotensin-converting enzyme and acid phosphatase levels and relative height at 36 months.
CONCLUSION: These data suggest that long-term high dose enzyme replacement therapy may be required to obtain sufficient improvement to maintain health among paediatric patients with severe Gaucher disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11195013     DOI: 10.1007/pl00008411

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  4 in total

1.  Successful treatment of Gaucher disease type 1 by enzyme replacement therapy over a 10-year duration in a Japanese pediatric patient: A case report.

Authors:  Yuji Oto; Takeshi Inoue; So Nagai; Shinichiro Tanaka; Hisashi Itabashi; Masahisa Shiraisihi; Akihisa Nitta; Nobuyuki Murakami; Hiroyuki Ida; Tomoyo Matsubara
Journal:  Exp Ther Med       Date:  2021-01-22       Impact factor: 2.447

Review 2.  New names for old disciplines.

Authors:  H Galjaard
Journal:  J Inherit Metab Dis       Date:  2002-05       Impact factor: 4.982

3.  A novel genotype c.1228C>G/c.1448C-1498C (L371V/Rec-NciI) in a 3-year-old child with type 1 Gaucher disease.

Authors:  Nabil A Yassin; Samar A Muwakkit; Ahmad O Ibrahim; Imad M Kayim; Mohammad-Zohair M Habbal; Nabil M Chamseddine; Khaled M Musallam; Ali I Shamseddine
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

4.  Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease.

Authors:  Marcio Andrade-Campos; Pilar Alfonso; Pilar Irun; Judith Armstrong; Carmen Calvo; Jaime Dalmau; Maria-Rosario Domingo; Jose-Luis Barbera; Horacio Cano; Maria-Angeles Fernandez-Galán; Rafael Franco; Inmaculada Gracia; Miguel Gracia-Antequera; Angela Ibañez; Francisco Lendinez; Marcos Madruga; Elena Martin-Hernández; Maria Del Mar O'Callaghan; Alberto Pérez Del Soto; Yolanda Ruiz Del Prado; Ignacio Sancho-Val; Pablo Sanjurjo; Miguel Pocovi; Pilar Giraldo
Journal:  Orphanet J Rare Dis       Date:  2017-05-03       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.